{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:17:51Z","timestamp":1778746671430,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-024-01572-7","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T19:01:39Z","timestamp":1728414099000},"page":"1617-1629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["D-Xylose Ameliorates Non-Alcoholic Fatty Liver Disease by Targeting Macrophage-expressed LYZ Gene"],"prefix":"10.1007","volume":"83","author":[{"given":"Guoxiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreemoy Kanti","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"3","key":"1572_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.32074\/1591-951X-242","volume":"113","author":"I Cataldo","year":"2021","unstructured":"Cataldo, I., Sarcognato, S., Sacchi, D., Cacciatore, M., Baciorri, F., & Mangia, A., et al. (2021). Pathology of non-alcoholic fatty liver disease. Pathologica, 113(3), 194\u2013202.","journal-title":"Pathologica"},{"issue":"9","key":"1572_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher, G., Byrne, C. D., & Tilg, H. (2020). NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 69(9), 1691\u2013705.","journal-title":"Gut"},{"issue":"2","key":"1572_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41575-020-00406-0","volume":"18","author":"MF Abdelmalek","year":"2021","unstructured":"Abdelmalek, M. F. (2021). Nonalcoholic fatty liver disease: another leap forward. Nature Reviews Gastroenterology & Hepatology, 18(2), 85\u20136.","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"9","key":"1572_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/imj.14709","volume":"50","author":"TD Huang","year":"2020","unstructured":"Huang, T. D., Behary, J., & Zekry, A. (2020). Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Internal Medicine Journal, 50(9), 1038\u201347.","journal-title":"Internal Medicine Journal"},{"issue":"1","key":"1572_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., & Yang, W., et al. (2022). Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocrine Disorders, 22(1), 63.","journal-title":"BMC Endocrine Disorders"},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3389\/fimmu.2020.01754","volume":"11","author":"R Bansal","year":"2020","unstructured":"Bansal, R., Mandrekar, P., Mohanty, S. K., & Weiskirchen, R. (2020). Editorial: Macrophages in liver disease. Frontiers in Immunology, 11, 1754.","journal-title":"Frontiers in Immunology"},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3389\/fimmu.2019.02852","volume":"10","author":"D van der Heide","year":"2019","unstructured":"van der Heide, D., Weiskirchen, R., & Bansal, R. (2019). Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Frontiers in Immunology, 10, 2852.","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"1572_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14728222.2022.2132145","volume":"26","author":"TL Laursen","year":"2022","unstructured":"Laursen, T. L., Mellemkj\u00e6r, A., M\u00f8ller, H. J., Gr\u00f8nb\u00e6k, H., & Kazankov, K. (2022). Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets, 26(8), 697\u2013705.","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"11","key":"1572_CR9","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1111\/febs.15877","volume":"289","author":"R Thibaut","year":"2022","unstructured":"Thibaut, R., Gage, M. C., Pineda-Torra, I., Chabrier, G., Venteclef, N., & Alzaid, F. (2022). Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. The FEBS Journal, 289(11), 3024\u201357.","journal-title":"The FEBS Journal"},{"issue":"2","key":"1572_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cmet.2019.11.013","volume":"31","author":"B Cai","year":"2020","unstructured":"Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., & Zheng, Z., et al. (2020). Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metabolism, 31(2), 406\u201321.e7.","journal-title":"Cell Metabolism"},{"issue":"11","key":"1572_CR11","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.7150\/thno.82607","volume":"13","author":"S Du","year":"2023","unstructured":"Du, S., Zhang, X., Jia, Y., Peng, P., Kong, Q., & Jiang, S., et al. (2023). Hepatocyte HSPA12A inhibits macrophage chemotaxis and activation to attenuate liver ischemia\/reperfusion injury via suppressing glycolysis-mediated HMGB1 lactylation and secretion of hepatocytes. Theranostics, 13(11), 3856\u201371.","journal-title":"Theranostics"},{"key":"1572_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1106875","volume":"13","author":"S Lv","year":"2022","unstructured":"Lv, S., Zhang, Z., Su, X., Li, W., Wang, X., & Pan, B., et al. (2022). Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4\/NF-\u03baB signaling pathway. Frontiers in Endocrinology, 13, 1106875.","journal-title":"Frontiers in Endocrinology"},{"issue":"6","key":"1572_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.gastrohep.2020.01.004","volume":"43","author":"S Chen","year":"2020","unstructured":"Chen, S., Li, X., Li, M., Mei, Q., Huang, J., & Wu, Z., et al. (2020). Mucosal expression of defensin-5, soluble phospholipase A2 and lysozyme in the intestine in a rat model of acute liver failure and its relationship to intestinal bacterial translocation. Gastroenterologia y hepatologia, 43(6), 293\u2013300.","journal-title":"Gastroenterologia y hepatologia"},{"issue":"4","key":"1572_CR14","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.7150\/thno.67174","volume":"12","author":"S Franz","year":"2022","unstructured":"Franz, S., Ertel, A., Engel, K. M., Simon, J. C., & Saalbach, A. (2022). Overexpression of S100A9 in obesity impairs macrophage differentiation via TLR4-NFkB-signaling worsening inflammation and wound healing. Theranostics, 12(4), 1659\u201382.","journal-title":"Theranostics"},{"key":"1572_CR15","doi-asserted-by":"crossref","unstructured":"Apostolova, E., Lukova, P., Baldzhieva, A., Delattre, C., Molini\u00e9, R., Petit, E., et al. Structural characterization and in vivo anti-inflammatory activity of fucoidan from cystoseira crinita (Desf.) Borry. Marine Drugs. 2022;20(11).","DOI":"10.3390\/md20110714"},{"key":"1572_CR16","doi-asserted-by":"crossref","unstructured":"Wang, K., Cui, X., Ling, X., Chen, J., Zheng, J., Xiang, Y., et al. D-Xylose blocks the broad negative regulation of XylR on lipid metabolism and affects multiple physiological characteristics in mycobacteria. International Journal of Molecular Sciences 2023;24(8).","DOI":"10.3390\/ijms24087086"},{"key":"1572_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101274","volume":"50","author":"A Zeigerer","year":"2021","unstructured":"Zeigerer, A. (2021). NAFLD - A rising metabolic disease. Molecular Metabolism, 50, 101274.","journal-title":"Molecular Metabolism"},{"key":"1572_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.carbpol.2019.02.080","volume":"213","author":"J Liu","year":"2019","unstructured":"Liu, J., Wu, C., Li, X., Yan, Q., Reaney, M. J. T., & Jiang, Z. (2019). Xylose rich heteroglycan from flaxseed gum mediates the immunostimulatory effects on macrophages via TLR2 activation. Carbohydrate Polymers, 213, 59\u201369.","journal-title":"Carbohydrate Polymers"},{"issue":"9","key":"1572_CR19","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1039\/D0FO02736G","volume":"12","author":"J Li","year":"2021","unstructured":"Li, J., Wang, T., Liu, P., Yang, F., Wang, X., & Zheng, W., et al. (2021). Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD. Food & Function, 12(9), 3898\u2013918.","journal-title":"Food & Function"},{"issue":"1","key":"1572_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-023-00445-w","volume":"9","author":"J Hu","year":"2023","unstructured":"Hu, J., Wu, Y., Kang, L., Liu, Y., Ye, H., & Wang, R., et al. (2023). Dietary D-xylose promotes intestinal health by inducing phage production in Escherichia coli. NPJ Biofilms and Microbiomes, 9(1), 79.","journal-title":"NPJ Biofilms and Microbiomes"},{"issue":"9","key":"1572_CR21","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/bph.15768","volume":"179","author":"Y Li","year":"2022","unstructured":"Li, Y., Zhao, D., Qian, M., Liu, J., Pan, C., & Zhang, X., et al. (2022). Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. British Journal of Pharmacology, 179(9), 2054\u201377.","journal-title":"British Journal of Pharmacology"},{"issue":"5","key":"1572_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.7861\/clinmed.2020-0696","volume":"20","author":"W Li","year":"2020","unstructured":"Li, W., & Alazawi, W. (2020). Non-alcoholic fatty liver disease. Clinical Medicine (London, England), 20(5), 509\u201312.","journal-title":"Clinical Medicine (London, England)"},{"issue":"8","key":"1572_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cppeds.2020.100844","volume":"50","author":"K McNeice","year":"2020","unstructured":"McNeice, K., & Sandberg, K. (2020). Updates in non-alcoholic fatty liver disease (NAFLD). Current Problems in Pediatric and Adolescent Health Care, 50(8), 100844.","journal-title":"Current Problems in Pediatric and Adolescent Health Care"},{"issue":"2","key":"1572_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","volume":"292","author":"R Paternostro","year":"2022","unstructured":"Paternostro, R., & Trauner, M. (2022). Current treatment of non-alcoholic fatty liver disease. Journal of Internal Medicine, 292(2), 190\u2013204.","journal-title":"Journal of Internal Medicine"},{"key":"1572_CR25","doi-asserted-by":"crossref","unstructured":"Elchaninov, A. V., Fatkhudinov, T. K., Vishnyakova, P. A., Lokhonina, A. V., Sukhikh, G. T. Phenotypical and functional polymorphism of liver resident macrophages. Cells 2019;8(9).","DOI":"10.3390\/cells8091032"},{"issue":"1","key":"1572_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12224","volume":"262","author":"R Gentek","year":"2014","unstructured":"Gentek, R., Molawi, K., & Sieweke, M. H. (2014). Tissue macrophage identity and self-renewal. Immunological Reviews, 262(1), 56\u201373.","journal-title":"Immunological Reviews"},{"issue":"9","key":"1572_CR27","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.immuni.2022.08.002","volume":"55","author":"M Guilliams","year":"2022","unstructured":"Guilliams, M., & Scott, C. L. (2022). Liver macrophages in health and disease. Immunity, 55(9), 1515\u201329.","journal-title":"Immunity"},{"issue":"1","key":"1572_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s43141-022-00383-8","volume":"20","author":"H Venkata Subbiah","year":"2022","unstructured":"Venkata Subbiah, H., Ramesh Babu, P., & Subbiah, U. (2022). Determination of deleterious single-nucleotide polymorphisms of human LYZ C gene: An in silico study. Journal Genetic Engineering & Biotechnology, 20(1), 92.","journal-title":"Journal Genetic Engineering & Biotechnology"},{"issue":"29","key":"1572_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215744120","volume":"120","author":"Z Gu","year":"2023","unstructured":"Gu, Z., Wang, L., Dong, Q., Xu, K., Ye, J., & Shao, X., et al. (2023). Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78. Proceedings of the National Academy of Sciences of the United States of America, 120(29), e2215744120.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"1572_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fimmu.2020.00322","volume":"11","author":"Z Shan","year":"2020","unstructured":"Shan, Z., & Ju, C. (2020). Hepatic macrophages in liver injury. Frontiers in immunology, 11, 322.","journal-title":"Frontiers in immunology"},{"issue":"9","key":"1572_CR31","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam, A., Mohammadian, S., Vazini, H., Taghadosi, M., Esmaeili, S. A., & Mardani, F., et al. (2018). Macrophage plasticity, polarization, and function in health and disease. Journal of cellular physiology, 233(9), 6425\u201340.","journal-title":"Journal of cellular physiology"},{"key":"1572_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-immunol-101320-031555","volume":"40","author":"KM Sheu","year":"2022","unstructured":"Sheu, K. M., & Hoffmann, A. (2022). Functional hallmarks of healthy macrophage responses: Their regulatory basis and disease relevance. Annual Review of Immunology, 40, 295\u2013321.","journal-title":"Annual Review of Immunology"},{"issue":"1","key":"1572_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/etm.2015.2873","volume":"11","author":"W Chen","year":"2016","unstructured":"Chen, W., Wang, X., Huang, L. I., & Liu, B. O. (2016). Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4\/NF-\u03baB signaling pathway. Experimental and Therapeutic Medicine, 11(1), 73\u20136.","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"5","key":"1572_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.arteri.2020.12.007","volume":"33","author":"M Ye","year":"2021","unstructured":"Ye, M., Tang, Y., He, J., Yang, Y., Cao, X., & Kou, S., et al. (2021). Alleviation of non-alcoholic fatty liver disease by Huazhi Fugan Granules is associated with suppression of TLR4\/NF-\u03baB signaling pathway. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 33(5), 257\u201366.","journal-title":"Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis"},{"issue":"5","key":"1572_CR35","first-page":"4635","volume":"18","author":"J Zhao","year":"2018","unstructured":"Zhao, J., Wang, Y., Wu, X., Tong, P., Yue, Y., & Gao, S., et al. (2018). Inhibition of CCL19 benefits non\u2011alcoholic fatty liver disease by inhibiting TLR4\/NF\u2011\u03baB\u2011p65 signaling. Molecular Medicine Reports, 18(5), 4635\u201342.","journal-title":"Molecular Medicine Reports"},{"key":"1572_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118335","volume":"260","author":"A Cheudjeu","year":"2020","unstructured":"Cheudjeu, A. (2020). Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19. Life Sciences, 260, 118335.","journal-title":"Life Sciences"},{"issue":"Pt 1","key":"1572_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/978-94-024-1079-2_49","volume":"975","author":"W Lee","year":"2017","unstructured":"Lee, W., Kang, N., Park, S. Y., Cheong, S. H., Chang, K. J., & Kim, S. H., et al. (2017). Xylose-taurine reduced suppresses the inflammatory responses in lipopolysaccharide-stimulated Raw264.7 macrophages. Advances in Experimental Medicine and Biology, 975(Pt 1), 633\u201342.","journal-title":"Advances in Experimental Medicine and Biology"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-024-01572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-024-01572-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-024-01572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T07:27:43Z","timestamp":1747639663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-024-01572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s12013-024-01572-7","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"18 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}